http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111363026-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74
filingDate 2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-111363026-B
titleOfInvention Method for enhancing affinity and stability of antigen polypeptide
abstract The invention discloses a method for enhancing the affinity and stability of antigen polypeptide, the high-efficiency presentation function of polypeptide HLA-I compound to T cell benefits from the stable interaction in the compound, compared with the affinity, the stability of HLA-I compound can reflect the immunogenicity. The invention can solve the problems of low affinity combination of a tumor specific antigen and an HLA-I molecule and poor stability of a combined polypeptide HLA-I molecule compound, is suitable for the antigen epitope modification of a tumor related antigen and a tumor neoantigen, and after single residues of amino acid residues at positions P1, P3-P9 of the HLA-I molecule restricted polypeptide epitope except position P2 are respectively replaced by His/Tyr/Trp, the affinity and the stability of the HLA-I molecule restricted polypeptide epitope are enhanced, and the specificity of the HLA-A2402 on the antigen polypeptide after residue replacement is not influenced, so the invention has higher clinical practice significance on the anti-tumor immunotherapy adopting the tumor specific polypeptide or the anti-tumor immunotherapy of T cell immunotherapy after T cell receptor modification according to the principle.
priorityDate 2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2413956-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101381402-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9060
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396492
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395493
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6057
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484026
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397426
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396422
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457586860
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397476
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457673812
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457673809
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394900
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457673817

Total number of triples: 30.